Language:

Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions

Turk patoloji dergisi, 2022-01, Vol.38 (1), p.9-015 [Peer Reviewed Journal]

COPYRIGHT 2022 Akdema Informatics and Publishing ;ISSN: 1018-5615 ;EISSN: 1309-5730 ;DOI: 10.5146/tjpath.2021.01538 ;PMID: 34514571

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions
Author: Hui, Monalisa ; Uppin, Shantveer G ; Kumar, K Karun ; Radhika, S ; Chandrasekhar, P ; Rao, K Nageshwara
Subjects: Bone Neoplasms - pathology ; Chondroblastoma - metabolism ; Chondroblastoma - pathology ; Denosumab ; Diagnosis ; giant cell tumor of bone ; Giant Cell Tumor of Bone - diagnosis ; Giant Cell Tumor of Bone - metabolism ; Giant Cell Tumor of Bone - pathology ; giant cell-containing lesions of bone ; Giant Cells - metabolism ; Giant Cells - pathology ; Humans ; Immunohistochemistry ; p63 ; Tumors
Is Part Of: Turk patoloji dergisi, 2022-01, Vol.38 (1), p.9-015
Description: To assess P63 expression in giant cell-containing lesions of the bone (GCLB) and to determine its utility in differentiating giant cell tumor of the bone (GCTB) from other GCLBs. Cases diagnosed as GCLB on histopathology were included in the study. P63 immunohistochemistry was performed in all the cases. The percentage of cells showing nuclear positivity was assessed in the non-giant cell component. Statistical analysis was performed using the Mann-Whitney U test. Of the total 53 cases studied, the majority were GCTBs (23), followed by 12 cases of chondroblastomas (CBL) and 18 other giant cell lesions (GCLs). All giant cell-containing lesions except one case of CBL and brown tumor of hyperparathyroidism (BTH) showed P63 staining in the non-giant cell component. However, the mean P63 labeling of GCT (52.6%) was higher compared to CBL (28.3%), aneurysmal bone cyst (ABC) (15.2%), non-ossifying fibroma (NOF) (24.5%), giant cell lesion of small bones (GCLSB) (11%), BTH (6.8%) and chondromyxoid fibroma (CMF) (12.3%), with a p-value of < 0.001. Although p63 was present in majority of the GCLBs, its percentage positivity was significantly higher in GCTB compared to the other GCLBs. The diagnosis of GCTB is likely if cut-off value of > 50% is applied.
Publisher: Turkey: Akdema Informatics and Publishing
Language: English
Identifier: ISSN: 1018-5615
EISSN: 1309-5730
DOI: 10.5146/tjpath.2021.01538
PMID: 34514571
Source: MEDLINE
Alma/SFX Local Collection
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions

COPYRIGHT 2022 Akdema Informatics and Publishing ;ISSN: 1018-5615 ;EISSN: 1309-5730 ;DOI: 10.5146/tjpath.2021.01538 ;PMID: 34514571

Searching Remote Databases, Please Wait